Ontex: The Covenant Is Now the Story

A 49% EBITDA collapse and another guidance cut turn a cost-recovery narrative into a balance-sheet test.

ONTEX.BR · Earnings Call · 2026-10-28

A miss that lands on the balance sheet

Ontex did not merely miss its own plan in the third quarter; it removed the cushion that had made the plan look financeable. Revenue was broadly stable at about €428 million, but volumes fell 5%, adjusted EBITDA dropped 49% to €26 million and the margin collapsed 5.3 percentage points to 6.1%. Management then cut full-year adjusted EBITDA to €143 million–€148 million from €165 million–€180 million. Laurent Nielly was blunt: “we have reported the results of a challenging quarter and a further revision of our outlook” — Laurent Nielly, CEO · 2026-10-28. The EBITDA decline is the headline; the low results are what forced the next conversation.

We are bringing down, therefore, the full year adjusted EBITDA range from EUR 165 million to EUR 180 million down to EUR 143 million to EUR 148 million.
Laurent Nielly, CEO · 2026-10-28

The more important number was not in the P&L. Net debt was reduced slightly, but leverage rose to 3.75x because trailing EBITDA fell. The RCF tests leverage at June and December with a 3.5x threshold and a one-time allowance up to 3.75x; September is not a test date, but it leaves little room. Stephane Re, the new CFO, said the company is “engaging with our banks to secure a temporary adjustment to the leverage covenant” — Stephane Re, CFO · 2026-10-28. That is the difference between a bad quarter and a balance-sheet event. temporary adjustment is now the operative phrase, and headroom is the thing management has least of. Liquidity of €272 million, including €82 million of cash and roughly 70% of the €270 million RCF undrawn, is adequate but not generous against a transformation program and a December test.

The ‘temporary’ cost story has lost its expiry date

In August 2025, management was still treating the fluff pulp spike as a blip: “we knew that those cost increases, they were momentarily cost increases” — Gustavo Calvo Paz, Chief Executive Officer · 2025-08-01. In February 2026, the promise was “gradual improvements throughout the year” — Geert Peeters, Chief Financial Officer (CFO) · 2026-02-12. By Q3 2026 raw material prices were up about 10% versus the start of the year, transport costs similarly, diesel had been high since March and the dollar had turned against the euro since mid-September. The cost line did not behave as a blip; it behaved as a cycle. Raw material costs and Raw material prices are back at the center of the story, and the market will now discount management’s ‘temporary’ language until pricing actually catches up. Pricing is the offset, but it is late. Price/mix added only about 1%, and management conceded that pricing actions had not made a significant contribution. Asked whether the industry could need five to six quarters to recover inflation, as in 2017, Nielly said “it's fair to assume that it will take another few quarters for that to be fully implemented” — Laurent Nielly, CEO · 2026-10-28. That is a meaningful concession from a team that had been guiding to sequential recovery. pricing action is happening, but not fast enough to protect the P&L, especially with weak consumer sentiment and competitors defending volume.

Russia moves from footnote to deconsolidation

Russia had been a 5%-of-sales footnote and a strategic-review item. In February, Nielly said it was “way too early to preclude any conclusion” — Laurent Nielly, Chief Executive Officer (CEO) · 2026-02-12. On 15 October, the Russian entity was placed under interim administration; Ontex remains legal owner but says it has effectively lost control, triggering deconsolidation from October. Pro forma, net debt falls about €10 million as €19 million of cash and €30 million of lease liabilities leave the balance sheet, and liquidity drops to €252 million. Q4 EBITDA contribution is likely minimal versus the €2 million originally expected. deconsolidation is a new, company-specific twist; it removes a small earnings stream but also a legal and reporting complication that management had previously kept at arm’s length.

The cost program is credible, but not fast enough

Focus to Value delivered €45 million year-to-date, including €16 million in Q3, toward a €240 million target by end-2028. White-collar positions outside manufacturing are to fall more than 20%, with about one-third completed or in execution; manufacturing is being exited in Australia and rightsized in Germany. These are real actions. But the savings offset only about 4% of the cost base, while raw materials and transport rose by roughly 10%. Focus to Value is the right program; it is simply not large enough to absorb a volume decline and a price lag at the same time. Fem Care volumes fell 12%, mostly planned contract exits in North America and overseas; Baby Care fell 9% on weak diaper demand and exits; Adult Care was stable, with European healthcare growth offsetting retail weakness. The Contract exits are deliberate, but they remove revenue before new contracts and price increases fully arrive. Q4 guidance of €39 million–€44 million assumes confirmed pricing, a modest easing in cost inflation, savings and seasonality. Management says there is no magic trick and no hedging benefit. Free cash flow guidance improved to zero to minus €10 million from minus €15 million to minus €25 million, helped by working capital and lower CapEx. That is a genuine positive, but it is also what you do when the covenant is tight. The story is no longer ‘cost inflation will pass.’ It is whether Ontex can get through the December covenant test without surrendering terms, and whether pricing and volume stabilize before the next guidance reset. The equity is small, the leverage is high, and the margin for error is thin.